WNT5A and osteosarcoma: Treating human osteoblast-like osteosarcoma SaOS-2 cells with rhWnt5a for 10 days reduced the mineralization capacity of these cells (S3 Fig), suggesting that Wnt5a has a direct effect on the mineralization potential of osteoblasts.